Longevity Health Holdings, Inc. (Nasdaq: XAGE), a company focused on human longevity and healthy aging through technologically innovative and clinically proven products in regenerative bio-aesthetics, diagnostics, and nutrition (“Longevity”, the “Company”, “we”, “our”, or “us”), announces the execution of a merger agreement (the “Merger”) with 20/20 BioLabs, Inc. (“20/20”), a leading provider of innovative laboratory tests for the early detection and the proactive management of chronic disease risk, to combine the companies in an all-stock transaction. Following the closing of the Merger (the “Closing”), the combined company is expected to continue to trade on Nasdaq under the symbol “XAGE.”
Read the full article: Longevity Health Holdings Announces Execution of Merger Agreement with 20/20 BioLabs //
Source: https://www.globenewswire.com/news-release/2025/04/14/3060883/0/en/Longevity-Health-Holdings-Announces-Execution-of-Merger-Agreement-With-20-20-Biolabs.html